Cerebrolysin is a cognitive & neuro research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Cerebrolysin is a porcine brain-derived peptide mixture produced by enzymatic digestion of purified porcine brain proteins, standardized to contain approximately 25% low-molecular-weight peptide fragments (primarily below 10 kDa) and 75% free amino acids. The low-molecular-weight peptide fraction is proposed to contain neurotrophic and neuroprotective components, including peptides with activity profiles similar to endogenous neurotrophic factors such as BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and CNTF (ciliary neurotrophic factor). This neurotrophic-like activity is the primary mechanistic hypothesis underlying cerebrolysin's research profile.
Preclinical research in rodent models of neurodegenerative conditions, ischemic brain injury, and traumatic brain injury has examined cerebrolysin's effects on neuronal survival, dendritic morphology, amyloid precursor protein (APP) processing, tau phosphorylation, and cognitive behavioral endpoints. Studies have documented increased BDNF and NGF protein levels in brain tissue of cerebrolysin-treated animals, and in vitro experiments with primary cortical and hippocampal neurons have shown protection against glutamate excitotoxicity and oxidative stress-induced cell death in cerebrolysin-treated cultures.
PeptidesFromChina.co supplies Cerebrolysin as a lyophilized powder preparation at standardized peptide content, verified by HPLC. Certificate of Analysis accompanies every batch. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | Standardized porcine brain-derived peptide mixture |
|---|---|
| Active Fraction | ~25% low-MW peptides (<10 kDa), 75% free amino acids |
| Proposed Active Components | Neurotrophic-like peptides, BDNF/NGF-related sequences |
| Research Areas | Neuroprotection, neurodegeneration models, ischemic brain injury, traumatic brain injury, cognitive aging |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (use within 24 hours) |
| CAS Number | N/A — complex mixture |
| Molecular Weight | N/A — complex mixture |
| Molecular Formula | N/A — complex mixture |
| Sequence | N/A — complex mixture |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Cerebrolysin | 60 mg | 6 vials | ≥98% | In Stock | $38.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Research has examined cerebrolysin's neuroprotective properties in primary cortical and hippocampal neuron cultures under conditions of glutamate excitotoxicity, oxygen-glucose deprivation, and oxidative stress. Studies have measured neuronal viability (MTT, LDH assays), mitochondrial function, and caspase activation. The proposed mechanism involves induction of endogenous BDNF and NGF expression and activation of TrkB/TrkA survival signaling pathways.
In rodent models of Alzheimer's disease-like pathology (APP/PS1 transgenic, intracerebroventricular streptozotocin), cerebrolysin has been studied for effects on amyloid-beta peptide production, tau hyperphosphorylation (pTau-Thr231, pTau-Ser396), and synaptic plasticity markers (PSD-95, synaptophysin). Research interest lies in whether the mixture's neurotrophic-like components can activate trophic signaling pathways that reduce amyloidogenic APP processing.
In rodent middle cerebral artery occlusion (MCAO) models of focal brain ischemia, cerebrolysin has been studied for effects on infarct volume, neurological deficit scoring, and long-term behavioral recovery. Research has examined timing-dependent effects (pre-ischemic versus post-ischemic administration) and the potential interaction between cerebrolysin and thrombolytic agents in reperfusion research contexts.
Cerebrolysin is a complex mixture and does not have a single molecular composition. The standardized preparation contains approximately 25% low-MW peptides (<10 kDa) and 75% free amino acids derived from porcine brain protein enzymatic hydrolysis. The specific neurotrophic-active peptide sequences within the mixture have not been fully characterized — this compositional complexity is both a practical limitation and a research question in itself.
Recombinant BDNF and NGF are single, structurally defined proteins with well-characterized receptor mechanisms (TrkB, TrkA). Cerebrolysin is a complex peptide mixture with proposed neurotrophic-like activity but without a defined single active molecule. Recombinant neurotrophins are preferred for mechanistic receptor studies; cerebrolysin is used in in vivo models where a mixture profile may more closely model the complexity of endogenous neurotrophic environments.
Cerebrolysin is supplied to standardized peptide content specifications, verified by HPLC. Certificate of Analysis from the manufacturing facility is included with every batch.
Lyophilized cerebrolysin should be stored at −20°C. Reconstituted solutions should be used within 24 hours. The complex mixture is less stable in solution than single-sequence peptides.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.